Clinical Trials Logo

Clinical Trial Summary

This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03399448
Study type Interventional
Source University of Pennsylvania
Contact EmergingMed
Phone 855-216-0098
Email PennCancerTrials@emergingmed.com
Status Recruiting
Phase Phase 1
Start date September 5, 2018
Completion date January 2033

See also
  Status Clinical Trial Phase
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Recruiting NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Active, not recruiting NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Not yet recruiting NCT03657420 - Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma Phase 1
Completed NCT02902965 - Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma Phase 2
Recruiting NCT03188172 - MUK Nine b: OPTIMUM Treatment Protocol Phase 2
Recruiting NCT02976493 - Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma N/A
Terminated NCT03218163 - MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma Phase 2
Active, not recruiting NCT02918331 - A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation Phase 1
Completed NCT01985126 - An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD Phase 2
Active, not recruiting NCT02852837 - Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy Phase 1
Active, not recruiting NCT00729118 - Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 1
Recruiting NCT03290950 - A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma Phase 2
Recruiting NCT03308474 - Myeloma Registry Platform (MYRIAM)
Recruiting NCT02902900 - An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Completed NCT01830816 - Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment Phase 1
Active, not recruiting NCT02849444 - A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance